Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review

Marchetti, Monia; Carobbio, Alessandra; Capitoni, Enrica; Barbui, Tiziano

doi:10.1002/ajh.25049

Cited by 35 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5] Blood and solid cancers occur in about 17% of patients with MPN, often preceding the diagnosis of MPN: melanoma, prostate cancer and non-MPN blood cancers have been diagnosed in excess as compared with control population in North Europe registry studies. In addition to these incident events, recent studies consistently reported that MPN patients are also prone to an increased risk of developing second cancers (SC).…”

Section: Introductionmentioning

confidence: 99%

“…In addition to these incident events, recent studies consistently reported that MPN patients are also prone to an increased risk of developing second cancers (SC). [1][2][3][4][5] Blood and solid cancers occur in about 17% of patients with MPN, often preceding the diagnosis of MPN: melanoma, prostate cancer and non-MPN blood cancers have been diagnosed in excess as compared with control population in North Europe registry studies. 6 We recently published the results from a nested case-control study with 647 MPN patients with SC and 1234 matched controls (MPN patients without SC) recruited from European LeukemiaNet (ELN) centers and reported that the exposure to cytoreductive drugs, such as hydroxyurea and ruxolitinib, increases the occurrence of nonmelanoma skin cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Second cancers in MPN: Survival analysis from an international study

et al. 2019

Self Cite

View full text Add to dashboard Cite

One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Second cancers in MPN: Survival analysis from an international study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…While the risk of transforming to acute leukemia has been the subject of several studies [2] less is known about the risk of developing other malignancies such as solid tumors. In this regard, the available information derives from retrospective cohort analysis [4][5][6][7][8][9][10] and registry-based population studies [11,12]. These latter may have limitations as they do not have access to information on individual treatment, mutational status, and other important clinical features.…”

mentioning

confidence: 99%

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

et al. 2019

Self Cite

View full text Add to dashboard Cite

We conducted a large international nested case-control study including 1,881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n=647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer and melanoma) and controls (n=1,234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR=1.06, 95% CI 0.82-1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had twofold higher risk of non-melanoma (NM) skin cancer (OR=2.28, 95% CI 1.15-4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR=3.74, 95% CI 1.00-14.01), ruxolitinib (OR=3.87, 95% CI 1.18-12.75) and for drug combination (OR=3.47, 95% CI 1.55-7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended.

show abstract

“…Among hematologic neoplasms, the risk is increased mainly for myeloid neoplasms; however, the risk for developing non‐Hodgkin lymphoma is also increased (hazard ratio 2.6) . A systematic review of published literature regarding concurrent MPN and LPN has recently been published . The authors analyzed single‐patient clinical data from 50 papers reporting 214 individuals harboring both MPN and LPN.…”

Section: Is There a Role For Cytoreductive Drugs For The Concomitant mentioning

confidence: 99%

Myeloproliferative and lymphoproliferative disorders: State of the art

Rumi

Baratè

Benevolo

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal disorders complicated mainly by vascular events and transformation to myelofibrosis (for PV and ET) or leukemia. Although secondary malignancies, in particular, lymphoproliferative disorders (LPNs), are rare, they occur at a higher frequency than found in the general population, and there has been recent scientific discussion regarding a hypothetical relationship between treatment with JAK inhibitors in MPN and the risk of development of LPN. This has prompted increased interest regarding the coexistence of MPN and LPN. This review focuses on the role of JAK2 and the JAK/STAT pathway in MPN and LPN, whether there is a role for the genetic background in the occurrence of both MPN and LPN and whether there is a role for cytoreductive drugs in the occurrence of both MPN and LPN. Furthermore, whether an increased risk of lymphoma development is limited to patients who receive the JAK inhibitor ruxolitinib, is a more general phenomenon that occurs following JAK1/2 inhibition or is associated with preferential JAK1 or JAK2 targeting is discussed.

show abstract

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review

Cited by 35 publications

References 20 publications

Second cancers in MPN: Survival analysis from an international study

Second cancers in MPN: Survival analysis from an international study

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Myeloproliferative and lymphoproliferative disorders: State of the art

Contact Info

Product

Resources

About